EMA's Committee for Medicinal Products for Human Use (CHMP) at its meeting on 26-29 In January 2026, he recommended the approval of six new medicines. Among them are Fylrevy (estetrol) for hormone replacement, Ilumira (lutetium (177Lu) chloride) for radiolabeling, Kayshild (semaglutide) for the treatment of non-cirrhotic metabolic liver dysfunction, dogexassocitin for the treatment of pediatric and adult patients, Supemtek (trivalent recombinant influenza vaccine prepared in cell culture). The CHMP issued positive recommendations to expand the therapeutic indications of Akeega (niraparib/acetate), Efmody (hydrocortisone), Eurneffy (adrenaline), Iclusig (ponatinib), Imfinzi, Kerendia (finerenone), Noxafil (posaconazole) and Zynyz (retifanlimab); for some, the decision of the European Commission is pending. Rezurock (belumosudil) has been re-examined as an orphan drug. EMA has started an Article 20 review of Tavneos for rare autoimmune diseases. Further updates on Mounjara (tirzepatide).